Advertisement
Screener

SUTRO BIOPHARMA, INC. (STRO) Debt Instrument, Interest Rate During Period

2.8 / 5 stars · 68/120 Roast Me

SUTRO BIOPHARMA, INC. Debt Instrument, Interest Rate During Period

SUTRO BIOPHARMA, INC. (STRO) reported Debt Instrument, Interest Rate During Period of 11.49% for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-25.

Discontinued › Notes › Debt › Debt Instruments

us-gaap:DebtInstrumentInterestRateDuringPeriod · last filed 2024-03-25

  • SUTRO BIOPHARMA, INC. debt instrument, interest rate during period for the quarter ending 2023-09-30 was 11.76%, a 36.27% increase year-over-year.
  • SUTRO BIOPHARMA, INC. debt instrument, interest rate during period for the quarter ending 2023-06-30 was 11.44%, a 41.76% increase year-over-year.
  • SUTRO BIOPHARMA, INC. debt instrument, interest rate during period for the quarter ending 2023-03-31 was 10.95%, a 35.69% increase year-over-year.
  • SUTRO BIOPHARMA, INC. debt instrument, interest rate during period for the quarter ending 2022-09-30 was 8.63%, a 6.94% increase year-over-year.
  • SUTRO BIOPHARMA, INC. debt instrument, interest rate during period for fiscal 2023 was 11.49%, a 31.77% increase from fiscal 2022.
  • SUTRO BIOPHARMA, INC. debt instrument, interest rate during period for fiscal 2022 was 8.72%, a 8.05% increase from fiscal 2021.
  • SUTRO BIOPHARMA, INC. debt instrument, interest rate during period for fiscal 2021 was 8.07%, a 0.12% decline from fiscal 2020.
  • SUTRO BIOPHARMA, INC. debt instrument, interest rate during period for fiscal 2020 was 8.08%, a 7.34% decline from fiscal 2019.
Period endDebt Instrument, Interest Rate During Period 3 monthDebt Instrument, Interest Rate During Period 6 monthDebt Instrument, Interest Rate During Period 9 monthDebt Instrument, Interest Rate During Period 12 month
2023-12-3111.49%
10-K · filed 2024-03-25
2023-09-3011.76%
10-Q · filed 2023-11-13
11.38%
10-Q · filed 2023-11-13
2023-06-3011.44%
10-Q · filed 2023-08-10
11.19%
10-Q · filed 2023-08-10
2023-03-3110.95%
10-Q · filed 2023-05-15
2022-12-318.72%
10-K · filed 2024-03-25
2022-09-308.63%
10-Q · filed 2023-11-13
8.26%
10-Q · filed 2023-11-13
2022-06-308.07%
10-Q · filed 2023-08-10
8.07%
10-Q · filed 2023-08-10
2022-03-318.07%
10-Q · filed 2023-05-15
2021-12-318.07%
10-K · filed 2024-03-25
2021-09-308.07%
10-Q · filed 2022-11-08
8.07%
10-Q · filed 2022-11-08
2021-06-308.07%
10-Q · filed 2022-08-08
8.07%
10-Q · filed 2022-08-08
2021-03-318.07%
10-Q · filed 2022-05-09
2020-12-318.08%
10-K · filed 2023-03-30
2020-09-308.07%
10-Q · filed 2021-11-10
8.08%
10-Q · filed 2021-11-10
2020-06-308.07%
10-Q · filed 2021-08-09
8.08%
10-Q · filed 2021-08-09
2020-03-318.09%
10-Q · filed 2021-05-07
2019-12-318.72%
10-K · filed 2022-02-28
2019-09-308.64%
10-Q · filed 2020-11-05
8.80%
10-Q · filed 2020-11-05
2019-06-308.87%
10-Q · filed 2020-08-06
8.88%
10-Q · filed 2020-08-06
2019-03-318.90%
10-Q · filed 2020-05-11
2018-12-318.39%
10-K · filed 2021-03-18

Similar stocks

Stock NameCountryMarket CapPE Ratio
Invivyd, Inc. (IVVD)United States$0.270B-2.42
PALISADE BIO, INC. (PALI)United States$0.275B-11.41
Lexeo Therapeutics, Inc. (LXEO)United States$0.278B-4.19
Lineage Cell Therapeutics, Inc. (LCTX)United States$0.241B-10.35
FATE THERAPEUTICS INC (FATE)United States$0.280B-2.51
Liminatus Pharma, Inc. (LIMN)United States$0.282B
Aligos Therapeutics, Inc. (ALGS)United States$0.238B-0.47
Inhibikase Therapeutics, Inc. (IKT)United States$0.296B-4.44
X4 Pharmaceuticals, Inc (XFOR)United States$0.297B-4.99
Protalix BioTherapeutics, Inc. (PLX)$0.221B9.87